作者: Jose J. Naveja , Abraham Madariaga-Mazón , Francisco Flores-Murrieta , Julio Granados-Montiel , Marco Maradiaga-Ceceña
DOI: 10.1016/J.DRUDIS.2020.10.018
关键词:
摘要: Several clinical trials to treat Coronavirus 2019 (COVID-19) are in progress around the world. Some of them rely on experience, whereas others include computational predictions. Here, we provide an overview current efforts search for COVID-19 therapies, focusing structural information relevant targets. We elaborate a robust pharmacological rationale repurposing existing drugs, highlighting key advantages dual therapies with antiviral and anti-inflammatory activity. Furthermore, consensus list molecules that could undergo preliminary randomized against COVID-19.